Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: A GOELAMS phase II study

Bone Marrow Transplantation

Volumn 26, Issue 9, 2000, Pages 971-977

  Colombat, Ph ^a   Cornillet, P ^b   Deconinck, E ^c   Tourani, J M ^d   Gardembas, M ^e   Delain, M ^a   Abgrall, J F ^f   Kootz, C ^a   Milpied, N ^g  

^a CHU BRETONNEAU   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^d Hopital Laennec   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f HÔTEL DIEU   (France)

^g NONE

Author keywords

Autologous stem cell transplantation; Chemotherapy; Follicular lymphoma; Minimal residual disease; Purging

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; VINDESINE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BODY BURDEN; BONE MARROW PURGING; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 0033759067     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702631     Document Type: Article

References (34)

1. Follicular lymphoma: Prognostic factors for response and survival
2. Natural history of and therapy of indolent non-Hodgkin's lymphoma
3. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
4. Benefit of autologous bone marrow transplantation, over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma in first complete remission
5. VACOP-B vs VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group
6. Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: Clinical impact of immunophenotype and in vitro purging
7. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent lymphoma
8. Value of autologous bone marrow transplantation in follicular lymphoma: A France Autogreffe retrospective study of 42 patients
9. Sequential high-dose therapy with peripheral blood progenitor cell support in low grade non-Hodgkin's lymphoma
10. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor prognosis follicular lymphoma
11. Significance of molecular marker-positive cells after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma
12. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
13. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
14. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin
15. Feasibility of autologous bone marrow transplantation for early consolidation of follicular non-Hodgkin's lymphoma
16. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission
17. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma
18. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting
19. + cells and their CD19 subsets in patients with follicular lymphoma
20. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
21. Doxorubicin-containing regimen with or without interferon alpha 2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial
22. Non-parametric estimation from incomplete observations
23. Autologous stem cell transplantation in follicular lymphoma with high tumor burden: A single center experience
24. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma
25. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: A case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry
26. + peripheral blood stem cell transplants for follicular lymphoma: A pilot study
27. + peripheral blood stem cells: Retained engraftment capability and reduced tumour cell content
28. Use of polymerase chain reaction and direct sequencing analysis to detect cells with the t(14;18) in autologous bone marrow from patient with follicular lymphoma, before and after in vitro treatment
29. Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma
30. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion
31. Detection by polymerase chain reaction of residual cells with the bc12 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B cell lymphoma
32. Significance of molecular marker-positive cells after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma
33. Correlation of Bc12 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma
34. Persistence of circulating t(14;18) cells in long-term remission after radiation therapy of localized stage follicular lymphomas